117 results on '"Castaman G"'
Search Results
2. The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia
3. PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach
4. OC 59.3 Pooled Safety Results from the Multidose Explorer Studies of Concizumab in Patients with Haemophilia
5. PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study
6. PB0650 Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Pediatric Patients with Hemophilia B: A Review of Results from Phase 3 Trial Studies
7. OC 52.5 Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec in Severe/Moderately Severe Hemophilia B: A Post Hoc Responder Analysis of Participants Who Received Full Dose and Responded to Treatment
8. OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates
9. PB0854 Could Gynecologists Contribute to an Increased Diagnosis of von Willebrand Disease among Women with Heavy Menstrual Bleeding?
10. PB0811 Natural Variants of von Willebrand Factor R1205 Associated with Type 1 von Willebrand Disease: In-Silico Docking Models and Energetics of the Interactions with the Macrophagic Scavenger Receptor LRP1
11. PB0642 Determinants of the Bleeding Phenotype in Persons with Non-Severe Hemophilia
12. Translational readthrough at F8 nonsense variants in factor VIII B domain contributes to residual expression and lowers inhibitor association
13. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
14. Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A
15. Pain relief with Eptacog beta in haemophilia patients with inhibitors
16. Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up
17. Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B
18. EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study
19. TREATMENT SATISFACTION AND JOINT HEALTH OUTCOMES WITHIN A REAL-WORLD HAEMOPHILIA B POPULATION: THE ADELPHI DISEASE SPECIFIC PROGRAMMESURVEY
20. LARGE DELETIONS IN THE F8 GENE PREDICT IMMUNE TOLERANCE INDUCTION FAILURE IN PEOPLE WITH SEVERE HEMOPHILIA A
21. GENETIC AND NON-GENETIC DETERMINANTS OF SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN PEOPLE WITH SEVERE HEMOPHILIA A
22. The bleeding phenotype in people with nonsevere hemophilia
23. S297: ASSESSING THE COST-EFFECTIVENESS OF LONG-TERM PROPHYLAXIS STRATEGIES IN VON WILLEBRAND DISEASE
24. Real-world clinical and psychosocial outcomes among people with mild or moderate haemophilia A treated on-demand in the Italian CHESS II cohort: a real-world data analysis
25. Adults With Haemophilia B and History of Chronic HCV/HBV Infection Receiving Etranacogene Dezaparvovec Gene Therapy in the HOPE-B Clinical Trial Demonstrate Long-Term Bleeding Protection and Sustained FIX Activity 3 Years After Administration.
26. T-13-13: Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A.
27. T-13-21: Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres < 1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B.
28. T-13-07: Pain relief with Eptacog beta in haemophilia patients with inhibitors.
29. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
30. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
31. Translational readthrough at F8 nonsense variants in factor VIII B domain contributes to residual expression and lowers inhibitor association
32. Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies.
33. Intracranial hemorrhage before start of prophylaxis in children with hemophilia: incidence, timing, and potential for prevention.
34. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.
35. The Unmet Needs of Lysosomal Storage Disorders from Early Diagnosis to Caregiving Pathways: An Italian Perspective.
36. Gene therapy for people with hemophilia B: a proposed care delivery model in Italy.
37. Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model.
38. Keep it positive: loss of positive charge induced by R1205H von Willebrand factor change accelerates von Willebrand factor clearance through enhanced binding to macrophage clearance receptors LRP1 and SR-A1.
39. Awareness of von Willebrand disease among gynecologists: Investigating the referral of women with heavy menstrual bleeding to hematologists.
40. Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B.
41. Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B.
42. Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.
43. Outcome measures in hemophilia: current and future perspectives.
44. Real-world experience of rIX-FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy - Results from IDEAL Part B.
45. Exposure-Response Relationship between VWF/FVIII Activity and Spontaneous Bleeding Events Following Recombinant VWF Prophylaxis in Severe VWD.
46. Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study.
47. Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives.
48. Physical Activity, Bleedings and Quality of Life in Subjects with Haemophilia A without Inhibitors-A Multicenter, Observational Italian Study with a Wearable Device.
49. Is pharmacological thromboprophylaxis necessary in persons with haemophilia undergoing major orthopaedic surgery?
50. Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.